- Digesting physical matrix barriers: Enzyme therapeutic considerations (e.g., collagenase) (1, 22)- Alter hyaluronan architecture and fragmentation (21)- Local chemokine modulation: T cell – tumor-cell centric drive (CCL5, CCL21, CXCL9, CXCL10) (20)- Blocking T-cell repression by the tumor glycocalyx (60, 61). The gene discussed is CXCL9; the disease is neoplasm.